This manuscript reviews current knowledge and recent findings regarding antibodyindependent functions of B cells in transplantation.
Introduction
The main biological hurdle to successful transplantation is the immune response of the recipient against the graft and the impact of that response on the graft. The immune response to allotransplantation includes powerful B-cell and T-cell responses that cause rejection in the absence of immunosuppression and/or sometimes protect grafts [1, 2] . Suppression of immunity by administration of immunosuppressive agents enables more than 90% of transplants to survive longer than a year. However, conventional immunosuppressive agents are more effective at preventing responses by T cells than responses by B cells and hence conventional therapies have little impact on antibody-mediated rejection. Furthermore, residual immunity, perhaps especially humoral immunity, can damage graft blood vessels over months to years leading to severe vascular disease, such as chronic rejection. Hence, much recent interest has focused on B-cell responses to transplantation and the impact of antibodies on the well being of grafts [3] . The reader is referred to a recent symposium on antibody-mediated rejection for consideration of this and related subjects [3] .
The relative importance of B cells in the outcome of transplants was first considered in classical studies that divided adaptive immunity into two distinct branches. Szenberg and Warner [4] compared immune responses of various types in normal chickens with immune responses in chickens from which either the bursa of Fabricius or the thymus was removed. Chickens lacking the bursa of Fabricius rejected skin grafts as quickly as chickens in which this structure was left intact, whereas chickens lacking a thymus accepted skin grafts permanently. These results led to the conclusion that graft rejection is thymus-dependent and bursa-independent, which was quickly embraced as a canon of immunology [5] [6] [7] . Recent experiments in animals and humans challenge the segregation of graft rejection into the domain of thymus-dependent functions. In fact, B cells produced by the bursa of Fabricius have the most profound impact on clinical organ graft transplants. Problems, such as acute and chronic humoral rejection, caused by alloreactive antibodies are among the greatest challenges in transplantation. Further, to the extent that antibodies induce accommodation, a condition in which the graft resists immunological injury [8, 9] , which may represent the most common outcome in transplantation, B cells determine the fate of most transplants. B cells and/or antibodies contribute to the rejection of skin allografts or organ allografts by different mechanisms. Skin allografts are fed predominantly by host blood vessels [10] and as a consequence they do not present vascular targets for alloantibodies. Instead rejection of skin grafts is dominated by cellular rejection [11] . In contrast, organ grafts are fed by blood vessels of the donor, and thus small amounts of alloantibody can generate complement-mediated vascular diseases [12, 13] , such as hyperacute or acute vascular rejection. How
B cells in transplantation
Recent work has generated contradictory evidence regarding the role of B cells in rejection of allografts. A recent study [17 ] identified a 'B-cell signature' associated with renal transplant tolerance in humans. Newell et al. [17 ] compared the gene expression profiles in peripheral blood lymphocyte subsets of tolerant renal transplant recipients (recipients with stable graft function who had taken no immunosuppressive agents for more than 1 year) with the profiles of patients with stable graft function who had taken immunosuppressive agents. The tolerant and nontolerant patients differed in the expression of three genes, IGKV4-1, IGLL1 and IGKV1D-13, which encode Ig light chain variable region gene segments. Newell et al. [17 ] suggested that expression of these genes may be utilized to identify transplant recipients to be weaned from immunosuppression. Because the expression of those genes in nontransplanted controls was comparable to their expression in tolerant patients, expression may result from immunosuppression as well as tolerance.
Zarkhin et al. [18] found that reduced graft survival and resistance to steroid therapy was associated with the presence of B lineage cells in grafts. Because CD20positive B cells in the graft expressed activation markers and major histocompatibility complex (MHC) class-II, Zarkhin et al. [18] suggested that B cells in the grafts might present donor antigen to T cells, amplifying antigraft immunity. These authors also found that presence of CD20-negative, CD38-positive plasmablasts and plasma cells infiltrating the grafts correlated with circulating donor-specific antibody and concluded that these cells might contribute to antibody-mediated rejection and steroid resistance.
How B cells impact in the immune responses to transplantation has been sought in mice by genetic engineering and in humans using B-cell-depleting agents. Experiments using B-cell-deficient mice have yet to generate definitive concepts regarding involvement of B cells in antibody dependent or antibody independent facets of allograft rejection. Studies in mice rendered B-cell deficient by targeted deletion of heavy chain constant region m membrane exons, the so-called mMT mice [19] , have failed to reveal any significant impact on the outcome of fully allogeneic skin transplants [20] or on the outcome of skin transplants disparate for minor histocompatibility antigens [20, 21] . Because mMT mice produce some antibodies [22] AbuAttieh et al. [20] investigated the outcome of skin grafts in JH -/mice which lack B cells and immunoglobulin completely, owing to a gene targeted deletion of the JH gene segments of the heavy chain loci [23] . AbuAttieh and colleagues [20] showed that JH -/-B-cell-deficient mice rejected skin grafts differing in major or minor histocompatibility antigens with the same kinetics as wild type. Normal rejection of skin grafts was even more surprising given the compromised lymphoid structures [24, 25] and the severe contraction in the diversity of the T-cell compartment [26] . The apparent lack of impact of B-cell and immunoglobulin deficiency on skin graft rejection might at a first glance suggest that B cells and immunoglobulin do not contribute to rejection of allografts. This conclusion may be premature however.
B cells have been found by some to impact on the outcome of organ transplants [27] [28] [29] [30] , but not by others [31] . Wasowska et al. [28] found that only 85% of the cardiac allografts were rejected within 14 days in mMT B-cell-deficient recipients, whereas all cardiac allografts were rejected in wild type recipients. The authors further demonstrated that wild type rejection of cardiac allografts could be restored in mMT recipients by administering donor-specific antibodies [28, 32] . Gareau et al. [30] studied the role of B cells in the development of vasculopathy of aortic grafts in mice and concluded that antibodies were required for vasculopathy. Kelishadi et al. [29] studied the outcome of heterotopic cardiac allografts in cynomolgus monkeys following pre-emptive anti-CD20 monoclonal antibody (mAb) therapy combined with the calcineurin inhibitor cyclosporine A (CsA). These studies [29] showed that CD20-positive B-cell depletion combined with CsA prolonged graft survival and attenuated allograft vasculopathy suggesting that B cells contribute both to acute and chronic rejection. Noorchashm et al. [27] compared the outcome of heterotopic cardiac transplants in mice engineered to prevent expression of MHC class II on B cells with the outcome in wild type mice. The former retained allogeneic grafts for more than 70 days, whereas the latter rejected grafts in 9.5 days. Noorchashm et al. [27] suggested that B cells contributed to rejection by 62 
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Key points
B cells contribute to immunity by producing antibodies and by antibody-independent functions. Antibody-independent functions of B cells include: lymphoid organogenesis, T-cell repertoire development, antigen presentation, production of cytokines, and regulation of T-cell-dependent immunity and inflammation. B-cell depletion may enhance or inhibit cellular immunity and thus B-cell depletion should be considered with the broader goal of regulating immunity, rather than simply to remove antibodies.
presenting antigen. In contrast, Nozaki et al. [31] reached a different conclusion. Their studies found that mice of mMT stock rejected cardiac and skin allografts with the same kinetics as wild type mice; however, mMT mice from which CD8 þ T cells were depleted retained cardiac allografts indefinitely, but still rejected skin grafts rapidly. Nozaki et al. [31] concluded that B cells are dispensable in CD4 T-cell-mediated organ graft rejection. However, in all the examples cited, since mMT mice are not completely B-cell-deficient and produce switched Ig isotypes [22] , one cannot exclude the possibility that antibodies could have influenced cardiac allograft survival in complex ways.
B-cell depletion therapies (with anti-human CD20 antibodies) in transplant recipients have brought more controversy to the functions of B cells in transplantation. Anti-human CD20 (rituximab) is a chimeric monoclonal antibody (mAb), composed of variable regions isolated from a murine clone (IDEC-2B8) linked to human IgG1 heavy chain and kappa light chain constant regions [33] . Anti-CD20 mAb was first used to treat non-Hodgkin's lymphoma. Rituximab binds with high affinity to CD20 on the surface of malignant and normal B cells, but not on other cells. CD20 is a transmembrane protein that functions as a calcium channel and is expressed from pre-B cell to mature B-cell stages [34, 35] . Rituximab cross-links CD20 depleting B cells by inducing antibody-dependent cell-mediated cytotoxicity [36] , complement-dependent cytotoxicity [35, 37] and/or apoptosis [35, 38] . Because the precursors of B cells and antibody secreting cells lack CD20, anti-CD20 mAb therapy spares developing B cells and plasma cells and preserves sera IgG [39 ] . A single administration of anti-CD20 mAb depleted peripheral human naive B cells for 3 months to 1 year, but depletion was less complete in secondary lymphoid tissues [40] . Glennie et al. [36] provide an excellent review on the mechanisms of anti-CD20 mAb B-cell depletion.
Anti-CD20 mAb therapy improved the outcome of antibody-mediated rejection [41] , reviewed in [42 ] and induction therapy of highly sensitized patients [42 ,43] . Although administration of anti-CD20 mAb is associated with a favorable outcome of transplants, it is unclear whether the clinical improvement observed was due to inhibition of production of donor-specific antibodies or inhibition of other functions of B cells.
Results of one trial using anti-CD20 mAb as induction therapy have challenged the idea that B cells play no role in cellular rejection [44 ] . Clatworthy et al. [44 ] found that 83% of patients treated with anti-CD20 mAb (rituximab) experienced cellular rejection, whereas only 14% of patients treated with an anti-CD25 experienced that condition. Acute cellular rejection was confirmed by biopsy and occurred in the first 3 months after transplan-tation. These results suggested that B cells might regulate immunity in ways not completely understood. The grafts of patients treated with anti-CD20 mAb contained higher concentrations of tumor necrosis factor a, interleukin 6 and interleukin 10 than grafts of controls. Clatworthy et al. [44 ] suggested that depletion of B cells with anti-CD20 mAb might cause release of pro-inflammatory cytokines, stimulating antigen presentation and T-cell activation. However, the results are also consistent with the possibility that B cells suppress inflammation and immunity, both being heightened by depletion.
Novel functions of B cells
Although antibodies produced by B cells clearly modify the outcome of organ grafts, other functions and products of B cells might do so as well. We refer to these functions as 'antibody-independent' to denote independence from actions of antibodies. In some cases however, the functions of B cells may depend more or less on the presence or stimulation of the B-cell receptor (BCR) or on use of the B-cell receptor to facilitate transport of antigen into the cell.
Lymphoid organogenesis
Lakkis and colleagues [45] found that rejection of organ allografts depends on the existence of lymphoid tissue which is necessary to permit T-cell activation. However, development of lymphoid tissue depends absolutely on the function of B cells, which produce lymphotoxin and which in turn generate lymphoid organogenesis [46] . We consider involvement of B cells in lymphoid organogenesis to be an antibody-independent function of B cells; thus B-cell-deficient mice, that is JH À/À mice, mMT and RAG-deficient mice, have grossly abnormal lymphoid organs [24, 46] which may impact the generation of immunity to transplants.
T-cell repertoire development
Cell-mediated immunity is thought to reflect at least in part the diversity of T-cell antigen receptors (TCR). In support of this concept are aberrations in the TCR repertoire found in conditions of immunodeficiency such as AIDS. Although the development of T cells was always thought to be independent of B cells (hence the use of 'B' and 'T' in classifying lymphocytes) [47] , Keshavarzi et al. [48] observed that mice lacking B cells have a reduced number of T cells in the thymus and periphery and suggested that B cells and/or immunoglobulins contribute to the selection of T cells in the thymus and their maintenance in the periphery. On the basis of this concept, João et al. [26] measured TCR diversity in B-celldeficient mice or mice with oligoclonal B-cell receptor repertoires [26] . B-cell-deficient mice had TCR repertoires contracted more than 10 000-fold compared with wild type and mice with oligoclonal B cells had TCR repertoires contracted 100-fold compared with wild type. Because TCR diversity could be restored either by adoptive transfer of diverse B cells or by administration of diverse Ig, the authors concluded that Ig diversity generates TCR diversity. As one potential mechanism through which B cells diversify the developing T-cell repertoire, João et al. [26] have proposed that B-cell receptors and Ig provide diverse peptides for positive selection of T cells in the thymus to maintain T cells in the periphery [26, 48] .
The extent to which B cells establish the repertoire of T cells that respond to a transplant is unknown. Because cellular immunity is predicated on the availability of diverse peptide-specific or self-MHC-specific T-cell receptors, one might predict that contraction of the Tcell repertoire should result in deficient cellular immunity. However, this prediction fails in some remarkable ways. As an example, children who undergo thymectomy and treatment with T-cell-depleting agents as a result of heart transplantation in infancy have profound contraction of T-cell diversity [49] . However, despite this contraction, recipients transplanted early in life are susceptible to rejection and do not suffer especially from opportunistic infection or other problems associated with immunodeficiency. In agreement with the conclusion that contractions of TCR do not cause defects in themselves, B cell and/or immunoglobulin-deficient mice can reject primary skin allografts as rapidly as wild type counterparts [20] . Thus, contraction of the T-cell repertoire may not by itself cause immunodeficiency because T cells adapt to repertoire contraction suffered early in life [49] . Rejection of allografts, however, can hardly be considered a sensitive test of cellular immunity because humans and mice with gross defects in cellular immunity such as DiGeorge or nude can still reject allografts [50] . However, defects in TCR diversity might yet be found to influence the outcome of allografts and the recipients of allografts in more subtle ways, especially when added to the impact of immunosuppressive therapy.
Antigen presentation
B cells can present antigen to T cells [51] [52] [53] . B cells express MHC class I and MHC class II complexes and costimulatory molecules, such as CD80 and CD86 [53] and OX40L [54] . B cells can prime and activate T cells almost as effectively as dendritic cells [51] . B-cell antigen presentation can lead to the clonal expansion of both B and T cells and may be necessary for the generation and maintenance of B-cell and T-cell memory [55] [56] [57] [58] .
B cells activate T cells in the same way as other antigenpresenting cells, that is, they take up and process proteins, present peptides associated with MHC class II to T cells and express costimulatory molecules. B cells can also activate T cells by a mechanism distinct from the mechanisms used by other antigen-presenting cells. In contrast to other antigen-presenting cells, B cells can take up antigen specifically via the B-cell receptor into the endosomal compartment [52] and as a consequence increase presentation of peptides from an antigen to which they have a unique specificity [51, 53] . Thus, MHC class II expressed by activated B cells can be enriched for peptides derived from the antigen recognized by the BCR. Lanzavecchia [59] showed that antigen-specific interaction between T cells and B cells required antigen-specific immunoglobulins and antigen processing, and promoted activation of MHC class II restricted T cells. Activation of T cells directed against fragments of the antigen internalized by the BCR and presented on the surface of B cells establishes a 'cognate' link between the T cell and B cell [59] . Cognate interaction might coordinate, amplify and coregulate the responses of B cells and T cells. Whether and to what extent cognate interactions account for immunity to transplantation is not known.
The role of B cells as antigen-presenting cells has been confirmed by several research groups [60] [61] [62] . More recent studies have generated controversy about whether antigen presentation by B cells contributes to T-cell priming in vivo. B cells may not be needed for presentation of protein and viral antigens that lead to priming CD4 T-cell responses that are measured by proliferation and cytokine production [21, 63, 64] . However, B cells are important for generating some CD4 T-cell responses to protein antigens [65, 66] . Activated B cells have been shown to skew T-cell responses toward Th2 and production of Th2-derived cytokines [67] [68] [69] . Thus, B cells appear to influence the fate of T cells depending on the environment and stimuli. In transplantation, the role of B cells in antigen presentation has been difficult to ascertain because B cells have a broad impact on development of lymphoid tissue and T cells, thus complete absence of B cells impacts in multiple facets of immunity.
Cytokine production
B cells produce multiple cytokines including IL-4, IL-6, IL-10, lymphotoxin-a, TGFb and IFNg [67, 70, 71] . How cytokine production by B cells is orchestrated in the regulation of immunity is not understood and the subject of current research.
B cells as regulators of T-cell-dependent immunity and inflammation
How exactly the antibody-independent functions of B cells might influence the outcome of cellular immunity to transplants has not been studied beyond potential involvement in antigen presentation, mentioned above.
However, some potential functions can be drawn from work testing antibody-independent functions of B cells in auto-immune diseases. For a comprehensive review, we recommend articles by Yanaba et al. [72] and Bouaziz et al. [73] .
Anti-CD20 mAb therapy has improved the outcome of auto-immune disorders with pathogenic antibodies such as neuropathies associated with auto-antibodies [74] , antifactor VIII syndrome [75] , mixed cryoglobulinemia [76] , myasthenia gravis [77] , Graves' disease [78] and Sjö gren's syndrome [79] to name a few. The possibility that antibody-independent functions of B cells might explain improvements in the manifestations of autoimmunity can be taken from investigation of the impact of anti-CD20 mAb on the outcome of T-cell-mediated autoimmune diseases such as diabetes and relapsing multiple sclerosis. Anti-CD20 mAb treatment has been found to preserve beta-cell function in patients with insulindependent diabetes mellitus. In this study, patients treated with anti-CD20 mAb showed improved endogenous insulin production, better control of glycemia and fewer diabetic complications [39 ] . Similarly, anti-CD20 mAb treatment decreased inflammatory brain lesions and clinical relapses in multiple sclerosis [80 ] without changing significantly the levels of IgM, IgG, and IgA [80 ] . These conclusions are consistent with a role for B cells in the regulation of immunity.
One antibody-independent function contributed by B cells in auto-immune disease may involve the interaction of B cells with T cells. Nonobese diabetes (NOD) prone mice develop diabetes owing to cellular immunity directed against insulin producing beta cells. NOD prone mice made B-cell deficient by breeding with the mMT strain have a lower incidence of diabetes [81] . Support for the idea that B cells contribute to initial priming and expansion of auto-immune T cells is found in a recent study in auto-immune regulator (AIRE)-deficient mice, a model for auto-immune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) [82] . Gavanescu et al. [82] found that AIRE-deficient mMT mice, AIREdeficient JH À/À mice, and AIRE-deficient mice treated with anti-CD20 mAb do not develop or develop less severe auto-immune APECED than B-cell proficient AIRE-deficient mice. Because depletion of B cells later in the course of disease ameliorated but did not reverse auto-immunity the authors propose that B cells contribute early in the development of disease, perhaps by helping to prime auto-immune T cells.
In an animal model of multiple sclerosis, the results of anti-CD20 mAb therapy were ambivalent. Although anti-CD20 mAb therapy administered after disease induction ameliorated experimental auto-immune encephalitis symptoms, the same treatment given prior to disease induction induced a more severe course [83] . In a separate study, Haas and colleagues [84] examined the effect of depleting CD20-positive B cells in a mouse model of human systemic lupus erythematosus. These authors found that spontaneous disease was delayed when B-cell depletion therapy was administered to mice aged between 12 and 18 weeks. In contrast, when B-cell depletion was administered to 4-week-old mice it hastened disease onset. These studies demonstrated that Bcell depletion can have opposite effects in the induction of protection or pathology, depending on when it occurs in the course of auto-immunity.
Antibody-independent B-cell functions might restrain some facets of immunity. As early as 1974, Katz et al.
[85] compared the magnitude of delayed-type hypersensitive (DTH) reactions in cyclophosphamide-treated recipients followed by transfer of ovalbumin primed B and/or T cells. These authors found that the magnitude of the DTH responses was decreased when B cells were transferred together with T cells compared with the magnitude of the DTH reactions obtained in recipients receiving T cells alone [85] . These studies suggested that B cells suppress cellular immunity. Mizoguchi [83] . B cells expressing CD1d hi CD5 þ CD19 hi regulate T-cell activation and inflammation through the production of IL-10 in an antigen-specific manner [70, 83, [87] [88] [89] . IL-10 suppresses production of pro-inflammatory cytokines by T cells, monocytes and macrophages [90] , inhibits proliferation of antigen specific T cells by decreasing antigen presentation by dendritic cells, macrophages, Langerhans cells and B cells [91] . Thus, mice deficient in IL-10 spontaneously develop inflammatory bowel disease [92] and IL-10 deficiency enhances the severity of several auto-immune and inflammatory disorders [93] [94] [95] . However, DiLillo et al. [96 ] proposed that IL-10 regulates immunity locally rather than systemically. Whether the properties of B cells in the regulation of immunity depend only on the production of IL-10 remains to be investigated.
What causes differentiation of regulatory B cells with immunosuppressive and anti-inflammatory properties is not known. IL-10 producing B cells might be generated as a consequence of polyclonal B-cell activation but regulation of inflammation and autoimmunity by B cells appears to be antigen specific [70, 83] . In fact, development of B regulatory cells requires a diverse BCR [73] . If the regulatory properties of B cells impact the fate of organ transplants, one would predict that B-cell depletion should exacerbate cellular allo-immunity. Consistent with this possibility is the work by Clatworthy et al.
[44 ] who observed enhanced cellular rejection following B-cell depletion therapy. However, enhanced cellular immunity may remain hidden in most transplant recipients undergoing T-cell-specific immunosuppression explaining why enhanced cellular immunity in the course of B-cell-depletion therapy has been reported only in a small number of cases.
Conclusion
Once B cells were thought merely to produce antibodies; however, recent studies indicate far more complex and sometimes contradictory functions of B cells. B cells organize lymphoid structures, generate T-cell diversity, present antigen and regulate immunity. Therefore, B-cell-depleting therapies could benefit but also compromise the outcome of organ transplants. Most knowledge about the antibody-independent functions of B cells derives from investigation of auto-immune diseases. However, clinical and basic research on autoimmunity is hindered by uncertainty regarding the onset of autoimmune response and the nature of antigens which provoke it.
In transplantation, the effects of immunity on the graft start at transplantation, thus defining a window in time for therapeutic intervention. The field of transplantation offers many new emerging tools to gain further important insights about novel, antibody-independent functions of B cells.
